{"entity":{"id":"dfp-10917","kind":"drug","name":"DFP-10917","aka":[],"tldr":"DFP-10917 is an experimental nucleoside analogue from Delta-Fly Pharma, in phase 3 trials for relapsed or refractory acute myeloid leukaemia; its current status is not stated.","summary":"DFP-10917 is a nucleoside analogue (continuous intravenous infusion) from Delta-Fly Pharma, with Nippon Shinyaku as licensee. A deoxycytidine-like nucleoside analogue given as a low-dose continuous infusion over 14 days. Its furthest stage is phase 3, for relapsed or refractory acute myeloid leukaemia. ClinicalTrials.gov registers it in 3 studies linked below. The phase 3 trial NCT03926624 in relapsed or refractory AML was TERMINATED: 'The data met the protocol-specified criteria for futility of the investigational treatment' (167 enrolled; completed 7 January 2026). A phase 1/2 with venetoclax (NCT06382168) has registry status UNKNOWN. No company statement on next steps was found. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Delta-Fly Pharma: delta-flypharma.co.jp","url":"https://www.delta-flypharma.co.jp/en/r-and-d"},{"label":"Delta-Fly Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT03926624"},{"label":"Delta-Fly Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06382168"},{"label":"ClinicalTrials.gov: trials of DFP-10917","url":"https://clinicaltrials.gov/search?intr=DFP-10917"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["delta-fly-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03926624","nct06382168","nct01702155"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DFP-10917","modality":"Nucleoside analogue (continuous intravenous infusion)","mechanism":"A deoxycytidine-like nucleoside analogue given as a low-dose continuous infusion over 14 days.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dfp-10917/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"company":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/"}],"trial":[{"id":"nct06382168","kind":"trial","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06382168/"},{"id":"nct01702155","kind":"trial","name":"Phase I/II Study of DFP-10917 in Patients With Acute Leukemia","route":"/trials/nct01702155/"},{"id":"nct03926624","kind":"trial","name":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","route":"/trials/nct03926624/"}]}}